Literature DB >> 21080817

Molecular diagnosis of acute myeloid leukemia.

Christopher D Watt1, Adam Bagg.   

Abstract

The diagnosis and classification of acute myeloid leukemia is multifaceted, requiring the integration of a variety of laboratory findings, with genetic approaches now firmly established as a central component. Molecular genetic technologies continue to evolve and provide additional tiers of both clarity and complexity. Many have rapidly moved into clinical laboratories; others remain as relevant discovery tools, while some are poised to take their place in diagnostic testing menus. Here, we attempt to synthesize the role of various testing modalities and exciting nascent fundamental discoveries, with a view as to how these might be integrated into the contemporary and future evaluation of this group of aggressive hematologic malignancies.

Entities:  

Mesh:

Year:  2010        PMID: 21080817     DOI: 10.1586/erm.10.85

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  4 in total

1.  Value of multifaced approach diagnosis and classification of acute leukemias.

Authors:  Silvana Angelescu; Nicoleta Mariana Berbec; Andrei Colita; Doina Barbu; Anca Roxana Lupu
Journal:  Maedica (Buchar)       Date:  2012-09

2.  Utility of cell population data (VCS parameters) as a rapid screening tool for Acute Myeloid Leukemia (AML) in resource-constrained laboratories.

Authors:  Harpreet Virk; Neelam Varma; Shano Naseem; Ishwar Bihana; Dmitry Sukhachev
Journal:  J Clin Lab Anal       Date:  2018-09-29       Impact factor: 2.352

3.  Making a meal of multiple mutations in acute myeloid malignancies.

Authors:  Gerald Wertheim; Adam Bagg
Journal:  J Mol Diagn       Date:  2011-09-09       Impact factor: 5.341

Review 4.  Molecular-based classification of acute myeloid leukemia and its role in directing rational therapy: personalized medicine for profoundly promiscuous proliferations.

Authors:  Gerald B W Wertheim; Elizabeth Hexner; Adam Bagg
Journal:  Mol Diagn Ther       Date:  2012-12       Impact factor: 4.074

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.